| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lyra Therapeutics, Inc.$0.75
-0.13 (-14.77%)
D 20Pipeline Score Overvalued Biotech · Clinical
Market Cap
878.57 K
EPS
-23.78
P/E Ratio
-
Value Trade
12.94 K
SEC Financials
Q4 2025Dilution Risk
Revenue
398.00 K
R&D Expenses
18.41 M
Operating CF
-28.86 M
Total Assets
36.11 M
Total Liabilities
46.83 M
Equity
-10.72 M
D/E Ratio
12,345
-61.63 %
Week
-63.33 %
1 Month
-87.4 %
3 Month
-92.24 %
6 Month
-99.93 %
5 Year
-99.95 %
All Time
Cash Data
Cash Position
15.89 M
Monthly Burn
2.40 M
Runway
3.5 mo
Burn Trend
SEC Filing
Mar 31, 2026
Overview
Volume
18.32 K
52 Week Range
0.48 - 37.50
% held by Insiders
7.93 %
% held by Institutions
13.67 %
Enterprise Value
10.20 M
Total Shares
1.64 M
Short %
0.46 %
Float Shares
1.34 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D20
Pipeline Score $0M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 18%
Micro Cap (rank 748 of 911)
Percentile RankLyra Therapeutics, Inc. faces pipeline headwinds (20/100), with $276M risk-adjusted pipeline value, led by LYR-210 in Chronic Sinusitis (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYR-210 Small molecule | Chronic Sinusitis | Phase 3 | NCT04041609 | 58% | $219M | COMPLETED | 449 | - | - | Feb 4, 2021 | - | Jul 25, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LYR-210 | chronic rhinosinusitis without nasal polyps | Phase 3 | 2025-10-06 | LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24; symptom improvement observed as early as week 4 Read More | Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study Read More | |
LYR-210 | chronic rhinosinusitis without nasal polyps | Phase 3 | 2025-10-06 | LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24; symptom improvement observed as early as week 4 Read More | Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study Read More | |
LYR-210 | chronic rhinosinusitis without nasal polyps | Phase 3 | 2025-10-06 | LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24; symptom improvement observed as early as week 4 Read More | Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LYRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LYRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How LYRA ranks across every disease it competes inCompetitive Position is a premium feature
See how LYRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial